Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity (CROSBI ID 289720)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Caocci, Giovanni ; Vignetti, Marco ; Patriarca, Andrea ; Breccia, Massimo ; Platzbecker, Uwe ; Palumbo, Giuseppe A. ; Stauder, Reinhard ; Cottone, Francesco ; Petranovic, Duska ; Voso, Maria Teresa et al. High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity // International journal of hematology, 112 (2020), 2; 141-146. doi: 10.1007/s12185-020-02920-y

Podaci o odgovornosti

Caocci, Giovanni ; Vignetti, Marco ; Patriarca, Andrea ; Breccia, Massimo ; Platzbecker, Uwe ; Palumbo, Giuseppe A. ; Stauder, Reinhard ; Cottone, Francesco ; Petranovic, Duska ; Voso, Maria Teresa ; Tafuri, Agostino ; Invernizzi, Rosangela ; Caers, Jo ; Luppi, Mario ; La Nasa, Giorgio ; Niscola, Pasquale ; Efficace, Fabio

engleski

High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity

We examined the association between serum ferritin (SF) levels and patient-reported functional aspects and symptoms, as measured by the EORTC QLQ-C30, in newly diagnosed patients with myelodysplastic syndromes (MDS). Analysis was conducted on 497 MDS patients who were classified in two groups based on the SF value of 1000 ng/mL. Clinically relevant differences of patient-reported functional and symptom scales were evaluated and classified as small, medium and large, based on established thresholds. Multivariable linear regression analysis was performed to account for potential confounding factors. Patients with SF of ≥ 1000 ng/mL reported statistically significant and clinically relevant worse outcomes across various health domains. Dyspnea was the symptom indicating the largest difference and mean scores of patients with higher and lower SF levels were 40 and 24.3, respectively (p = 0.005), indicating a large clinically relevant difference (Δ = 15.7). Further research is needed to better understand the relationship between SF levels and specific health-related quality of life domains.

Functional status ; Myelodysplastic syndromes ; Quality of life ; Serum ferritin ; Symptoms ; Transfusion

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

112 (2)

2020.

141-146

objavljeno

0925-5710

10.1007/s12185-020-02920-y

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost